CAI CAI
Company Profile ↓Company Overview
CAI (CAI) is a publicly traded company listed on . The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Revenue has grown at a 46.5% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $812.03M (+97.0% YoY); net profit $-68.09M.
- Trailing 12 Months Year-on-year growth — revenue +97.0%.
- 5-Year Trend Long-term compounding — revenue CAGR 46.5%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 46.46% |
| 1 Year: | 96.97% |
Stock Price Performance
| 1 Year: | -44.22% |
| 6 Months: | -29.09% |
| 3 Months: | -13.19% |
| 1 Month: | -5.84% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)50.00 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 46.5% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 58.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | 100.05M | 101.62M | 120.92M | 181.40M | 216.83M | 216.17M |
| Operating Income | -67.01M | -60.84M | -57.95M | -17.99M | 32.64M | 5.28M |
| Net Income | -66.19M | -67.73M | -102.58M | -71.79M | 24.32M | -510.00K |
| Diluted EPS | -2.54 | -2.59 | -3.57 | -7.97 | 0.08 | 0.00 |
| R&D Expense | 24.79M | 27.64M | 23.07M | 25.05M | 21.62M | 31.32M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 258.49M | 306.13M | 412.26M | 812.03M |
| Cost of Revenue | 178.46M | 216.82M | 233.48M | 272.87M |
| Gross Profit | 80.02M | 89.31M | 178.78M | 539.17M |
| Operating Expenses | 395.78M | 408.86M | 435.90M | 494.06M |
| Operating Income | -315.76M | -319.55M | -257.12M | 45.11M |
| EBITDA | -245.89M | -260.80M | -182.95M | 11.38M |
| Interest Expense | 26.68M | 31.61M | 50.02M | 56.85M |
| Pretax Income | -320.83M | -341.42M | -281.89M | -68.09M |
| Tax Provision | 0 | 0 | 0 | 0 |
| Net Income | -320.83M | -341.42M | -281.89M | -68.09M |
| Diluted EPS | -1.57 | -1.82 | -1.36 | -3.22 |
| R&D Expense | - | 116.88M | 113.92M | 101.58M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Total Assets | - | - | 343.73M | 1.13B |
| Total Equity | -1.70B | -2.14B | -2.50B | 577.31M |
| Cash & Equivalents | - | - | 63.95M | 796.27M |
| Long Term Debt | - | - | 319.44M | 378.82M |
| Total Liabilities | - | - | 620.92M | 548.36M |
| Current Liabilities | - | - | 165.42M | 127.14M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|
| Operating Cash Flow | -276.10M | -245.20M | 83.16M |
| Investing Cash Flow | 214.77M | 52.93M | -16.26M |
| Financing Cash Flow | 10.13M | 200.29M | 664.99M |
| Capital Expenditure | -22.32M | -8.44M | -16.26M |
| Free Cash Flow | -298.42M | -253.64M | 66.89M |
| Share Buybacks | 0 | 0 | 113.00K |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | 31.0% | 29.2% | 43.4% | 66.4% |
| Operating Margin % | -122.2% | -104.4% | -62.4% | 5.6% |
| Net Margin % | -124.1% | -111.5% | -68.4% | -8.4% |
| ROE % | 18.8% | 15.9% | 11.3% | -11.8% |
| ROCE % | - | - | -144.2% | 4.5% |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CAI
Caris Launches Multi-Cancer Blood Test; Q2 Cases Total About 59,200 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxOTk5BUFdDelEzRWtSN0xjVWZMNHEtN1VTNm5wR0YtS0xMZkI4NFM3VkZReUtxbzBybXZLamNFN0Rqcmt6SzloTlZaOExNU3piMUtDQzh6MDNPdURLTF84bHlMVjd0SUZWZXpxZjh3MTd5eGJIN3N2ZUVuQXJ3M194WVRudkhjelh4VDdNcl…
Caris Life Sciences (CAI) Stock Looks Undervalued On A 47% Slump - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxNd3VkT25zNzRGYVdWeXJCZC0xWXJCbXNyMjNUREdmOVBHeUk3WnZjaUNSRWpUVkxxcTBCWktmTl9CdmIxR1c3aUpJRkpHdGZMNUJOcllwckEyeTY4Y0V3dmNjSHc4NjlMNHd6ZlNobTJvdk9Ud1B6NFpZV3Z0Yl9ic0ZhY3c3dllMMkFaMH…
Cairo Communication (BIT:CAI) Stock Faces Margin Squeeze After Wider Quarterly Loss - webull.com
<a href="https://news.google.com/rss/articles/CBMiWEFVX3lxTE91OTBtM0FUVzNNREw1ZmpDMUVJVlVnU1NfQU9LSGZtbnVZRjBSYXpsbFlYUlVUa1Jxd0xTU2FwNTBnOVAzdXEwZlM0ZkdLZnlmUGNaM2xZYW8?oc=5" target="_blank">Cairo Communication (BIT:CAI) Stock Faces Margin…
Renaissance Technologies LLC Acquires 120,000 Shares of Caris Life Sciences, Inc. $CAI - MarketBeat
<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxNNjZSUDlZRmo4VE9ieFdzRVR0MEJCYVlDY2tCcHRlYVJUSjJUbjBuMnJ0VjBIQ2dfSDdNLU04QVRqcmJhbDJjVlN0UXUxOV84Y185Y29mZFI5cm12NVlDVG5UY2NsRDdrbWNSS2JpZkYxTDlIREJmVjlscy15VVFidWptYktiS0ZwdFNFSU…
Caris Life Sciences (CAI) Sets August Results Date, Is The Stock Undervalued? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxOS050VHA5bklaNkM1bWxTZTVyU3hjTmppd19Td0NDRHVIUXlGT1BEMkoxY0otTUJ3Ylo1N1pubDg2Z2R5U1oyb0Y1dEhEQVh4WTV5aTh1a3JNcG43RTZzVld1UUFBMjJPRUY4WEpYLWR0X2VqOUttSE4wMVoxNUJqYUpRSUlWZVFBbHV3S2…
Caris Life Sciences, Inc. (NASDAQ:CAI) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
<a href="https://news.google.com/rss/articles/CBMi2wFBVV95cUxOcm1VUXZQTU1ZWTFxXzNJX29HZ05icVZzZWJ5QWVEMjdQMG1mRHZGUjlvVzNUcktQMVgyb2c4ZHRYTGwxSVdEYWk3bXg2Z3Nsd1RaZGFSLUVzT3FCcG9VNURtcDJKNVFXd2FhdjM0R0NrMjZSNUdmS1d6VnYxMUpyRFlmcXlSekduQnlyaW…
CAI — Frequently Asked Questions
What is the current share price of CAI?
As of 2026-08-05 17:25 PDT, CAI trades at $16.45 on NASDAQ/NYSE. Its 52-week range is $14.55 to $39.30.
What is the P/E ratio of CAI?
CAI trades at a trailing price-to-earnings (P/E) ratio of -5.11.
What is the return on equity (ROE) of CAI?
CAI has a return on equity (ROE) of -11.79%. Its return on capital employed (ROCE) is 4.52%.
Is CAI a good stock to buy?
This page provides a data-driven analysis of CAI, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.